Neuropharmacology and potential efficacy of new treatments for tobacco dependence

Bibliography

• BALFOUR DJK, BENWELL MEM, BIRRELL CE, KELLY RJ, AL-ALOUL M: Sensitization of the mesoaccumbens dopamine response to nicotine. Pharmacol. Biochem. Behav. (1998) 59:1021-1030.
   PubMed Web of Science ®Google Scholar
• BALFOUR DJK, RIDLEY DL: The effects of nicotine on neural pathways implicated in depression: a factor in nicotine addiction? Pharmacol. Biochem. Behav. (2000) 66:79-85.
   Web of Science ®Google Scholar
• BALFOUR DJK: The neurobiology of tobacco dependence: a preclinical perspective on the role of the nucleus accumbens. Nic. Tob. Res. (2004) 6:899-912.
   PubMed Web of Science ®Google Scholar
• CLARKE PBS, KUMAR R: The effects of nicotine on locomotor activity in nontolerant and tolerant rats. Br. J. Pharmacol. (1983) 78:329-337.
   PubMed Web of Science ®Google Scholar
• CLARKE PBS: Dopaminergic mechanisms in the locomotor stimulant effects of nicotine. Biochem. Pharmacol. (1990) 40:1427-1432.
   PubMed Web of Science ®Google Scholar
• CAGGIULA AR, DONNY EC, WHITE AR et al.: Cue dependency of nicotine self-administration and smoking. Pharmacol. Biochem. Behav. (2001) 70:515-530.
   PubMed Web of Science ®Google Scholar
• KENNY PJ, MARKOU A: Neurobiology of the nicotine withdrawal syndrome. Pharmacol. Biochem. Behav. (2001) 70:531-549.
   PubMed Web of Science ®Google Scholar
• MALIN DH: Nicotine dependence studies with a laboratory model. Pharmacol. Biochem. Behav. (2001) 70:551-559.
   PubMed Web of Science ®Google Scholar
• DI CHIARA G, IMPERATO A: Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Nat. Acad. Sci. (1988) 85:5274-5278.
   PubMed Web of Science ®Google Scholar
• CORRIGALL WA, FRANKLIN KJB, COEN KM, CLARKE PBS: The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (1992) 107:285-289.
   PubMed Web of Science ®Google Scholar
• CORRIGALL WA, COEN KM, ADAMSON KL: Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area. Brain Res. (1994) 653:278-284.
   PubMed Web of Science ®Google Scholar
• CADONI C, DI CHIARA G: Differential changes in the accumbens medial shell and core dopamine in behavioural sensitization to nicotine. Eur. J. Pharmacol. (2000) 387:R23-R25.
   PubMed Web of Science ®Google Scholar
• IYANIWURA TT, WRIGHT AE, BALFOUR DJK: Evidence that mesoaccumbens dopamine and locomotor responses to nicotine in the rat are influenced by pre-treatment dose and strain. Psychopharmacology (2001) 158:73-79.
   PubMed Web of Science ®Google Scholar
• DI CHIARA G: Behavioural pharmacology and neurobiology of nicotine reward and dependence. In: Handbook of Experimental Pharmacology: Neuronal Nicotinic Receptors. Clementi C, Fornasari D, Gotti C (Eds) Springer, Berlin, Germany (2000) 14:603-750.
   Google Scholar
• DI CHIARA G: Nucleus accumbens medial shell and core dopamine: differential role in behavior and addiction. Behav. Brain Res. (2002) 137:75-114.
   PubMed Web of Science ®Google Scholar
• ITO R, ROBBINS TW, EVERITT BJ: Differential control over cocaine-seeking behaviour by nucleus accumbens core and shell. Nat. Neurosci. (2004) 7:389-397.
   PubMed Web of Science ®Google Scholar
• ITO R, DALLEY JW, HOWES SR, ROBBINS TW, EVERITT BJ: Dissociation in conditioned dopamine release in the nucleus accumbens core and medial shell in response to cocaine cues and during cocaine-seeking behaviour in rats. J. Neurosci. (2000) 20:7489-7495.
   PubMed Web of Science ®Google Scholar
• BENWELL MEM, BALFOUR DJK, BIRRELL CE: Desensitisation of nicotine-induced dopamine responses during constant infusion with nicotine. Br. J. Pharmacol. (1995) 114:211-217.
   Google Scholar
• PIDOPLICHKO V, DE BIASI M, WILLIAMS JT, DANI J: Nicotine activates and desensitizes midbrain dopamine neurones. Nature (1997) 390:401-404.
   PubMed Web of Science ®Google Scholar
• CAGGIULA AR, DONNY EC, CHAUDRI N et al.: Importance of nonpharmacological factors in nicotine self-administration. Physiol. Behav. (2002) 77:683-687.
   PubMed Web of Science ®Google Scholar
• DONNY EC, CHAUDHRI N CAGGIULA AR et al.: Operant responding for a visual reinforcer in rats is enhanced by noncontingent nicotine: implications for nicotine self-administration and reinforcement. Psychopharmacology (2003) 169:68-76.
   PubMed Web of Science ®Google Scholar
• ROSE JE, BEHN FM, LEVIN ED: Role of nicotine dose and sensory cues in the regulation of smoke intake. Pharmacol. Biochem. Behav. (1993) 44:891-900.
   PubMed Web of Science ®Google Scholar
• ROSE JE, BEHN FM, WESTMAN EC, JOHNSON M: Dissociating nicotine and nonnicotine components of cigarette smoking. Pharmacol. Biochem. Behav. (2000) 67:71-81.
   PubMed Web of Science ®Google Scholar
• MALIN DH, LAKE JR, NEWLIN-MAULTSY P et al.: Rodent model of nicotine abstinence syndrome. Pharmacol. Biochem. Behav. (1992) 43:779-784.
   PubMed Web of Science ®Google Scholar
• MALIN DH, LAKE JR, CARTER VA et al.: The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome. Psychopharmacology (1994) 115:339-342.
   Google Scholar
• MALIN DH: Nicotine dependence studies with a laboratory model. Pharmacol. Biochem. Behav. (2001) 70:551-559.
   PubMed Web of Science ®Google Scholar
• HILDEBRAND BE, NOMIKOS GG, HERTEL B, SCHILSTRÖM B, SVENSSON TH: Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res. (1998) 779:214-225.
   PubMed Web of Science ®Google Scholar
• EPPING-JORDAN MP, WATKINS SS, KOOB GF, MARKOU A: Dramatic decreases in brain reward function during nicotine withdrawal. Nature (1998) 393:76-79.
   PubMed Web of Science ®Google Scholar
• CHIAMULERA C, BORGO C, FALCHETTO S, VALERIO E, TESSARI M: Nicotine reinstatement of nicotine self-administration after long-term extinction. Psychopharmacology (1996) 127:102-107.
   PubMed Web of Science ®Google Scholar
• COE JW, BROOKS PR, VETELINO MG et al.: Varenicline: an α4 β2 nicotinic receptor partial agonist for smoking cessation. J. Med. Chem. (2005) 48:3474-3477.
   PubMed Web of Science ®Google Scholar
• SCHARFENBERG G: [Cytisine (Tabex) as a pharmaceutical aid in stopping smoking]. Deutsche Gesundheitswesen. (1971) 26:463-465.
   PubMedGoogle Scholar
• TAPPER AR, McKINNEY SL, NASHIMI R et al.: Nicotine activation of α4 receptors: sufficient for reward, tolerance, and sensitization. Science (2004) 306:1029-1032.
   PubMed Web of Science ®Google Scholar
• PICIOTTO MR, ZOLI M, RIMONDI R et al.: Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature (1998) 39:173-177.
   Google Scholar
• COHEN G, ROUX JC, GRAILHE R et al.: Perinatal exposure to nicotine causes deficits with a loss of nicotinic receptor function. Proc. Natl. Acad. Sci. USA (2005) 102:3817-3821.
   PubMed Web of Science ®Google Scholar
• COHEN C, BERGIS OE, GALLI F et al.: SS591813, a novel selective and partial α4 β2 nicotinic receptor agonist with potential as an aid to smoking cessation. J. Pharmacol. Exp. Ther. (2003) 306:407-420.
   PubMed Web of Science ®Google Scholar
• ONCKEN C, WATSKY E, REEVES K et al.: Smoking cessation with varenicline, a selective nicotinic receptor partial agonist: results from a Phase II study. Proceedings of the 11 Annual Meeting of the Society for Research on Nicotine and Tobacco, Prague, Czech Republic (2005).
   Google Scholar
• ONCKEN C, WATSKY E, REEVES K et al.: Varenicline is efficacious and well tolerated in promoting smoking cessation: results from a 7-week, randomized, placebo-and bupropion-controlled trial. Proceedings of the 11 Annual Meeting of the Society for Research on Nicotine and Tobacco, Prague, Czech Republic (2005).
   Google Scholar
• TONSTAD S, HAYS JT, JORENBY DE et al.: Smoking cessation efficacy and safety of an α4 beta2 nicotinic receptor partial agonist – Results from varenicline in cessation therapy. Annual Meeting of the American Heart Association, Chicago, USA (November 15 2005).
   Google Scholar
• ALONSO R, VOUTSINOS B, FOURNIER M et al.: Blockade of cannabinoid receptors by SR141716 selectivity increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function. Neuroscience (1999) 91:607-620.
   PubMed Web of Science ®Google Scholar
• COLOMBO G, AGABIO R, DIAZ G: Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci. (1998) 63:113-117.
   Web of Science ®Google Scholar
• KIRKHAM TC, WILLIAMS CM, FEZZA F et al.: Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br. J. Pharmacol. (2002) 136:550-557.
   PubMed Web of Science ®Google Scholar
• COHEN C, PERRAULT G, VOLTZ C, STEINBERG R, SOUBRIE P: SR141716, a central cannabinoid (CB1) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine. Behav. Pharmacol. (2002) 13:451-463.
   PubMed Web of Science ®Google Scholar
• COHEN C, PERRAULT G, GRIEBEL G, SOUBRIE P: Nicotine-associated cues maintain nicotine-seeking behaviour in rats several weeks after nicotine withdrawal; reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology (2005) 30:145-155.
   PubMed Web of Science ®Google Scholar
• COHEN C, KODAS E, GRIEBEL G: CB(1) receptor antagonists for the treatment of nicotine addiction. Pharmacol. Biochem. Behav. (2005) 81:387-395.
   PubMed Web of Science ®Google Scholar
• ANTHENELLI RM, DESPRES JP: Effects of rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US Trial (smoking cessation in smokers motivated to quit). American College of Cardiology 53rd Annual Scientific Session, New Orleans, USA (2004).
   Google Scholar
• VAAN GAAL LF, RISSANRN AM, SCHEEN AJ et al.: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience fm the RIO-Europe study. Lancet (2005) 365:1389-1364.
   PubMed Web of Science ®Google Scholar
• DIMARZO V, MATIAS I: Endocannabinoid control of food intake and energy balance. Nat. Neurosci. (2005) 8:585-589.
   PubMed Web of Science ®Google Scholar
• PENTEL P, MALIN D, ENNIFAR et al.: A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioural and cardiovascular effects in rats. Pharmacol. Biochem. Behav. (2000) 65:191-198.
   PubMed Web of Science ®Google Scholar
• CARRERA MR, ASHLEY JA, HOFFMAN TZ et al.: Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg. Med. Chem. (2004) 12:563-570.
   PubMed Web of Science ®Google Scholar
• DEVILLERS SHL, LINDBLOM N, KALAYANOV G et al.: Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration (2002) 69:247-253.
   PubMed Web of Science ®Google Scholar
• LESAGE MG, KEYLER DE, HIEDA Y et al.: Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology (2005) (In Press).
   Google Scholar
• LINDBLOM N, DEVILLIERS SHL, KAKAYANOV G et al.: Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration (2002) 69:254-260.
   PubMed Web of Science ®Google Scholar
• HATSUKAMI D, RENNARD S, JORENBY D et al.: Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin. Pharmacol. Ther. (2005) 78(5):456-467.
   PubMed Web of Science ®Google Scholar
• ANDREOLI M, TESSARI M, PILLA M, VALERIO E, HAGAN JJ, HEIDBREDER CA: Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behaviour. Neuropsychopharmacology (2003) 28:272-1280.
   Google Scholar
• LE FOLL B, SOKOLOFF P, STRAK H, GOLDBERG SR: Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. Neuropsychopharmacology (2005) 30:720-730.
   PubMed Web of Science ®Google Scholar
• LE FOLL B, GOLDBERG SR, SOKOLOFF P: The dopamine D3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology (2005) 49:525-541.
   Google Scholar
• LE FOLL B, FRANCES H, DIAZ J et al.: Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur. J. Neurosci. (2002) 15:2016-2026.
   PubMed Web of Science ®Google Scholar
• LE FOLL B, DIAZ J, SOKOLOFF P: Increased dopamine D3 receptor expression accompanying behavioural sensitization to nicotine in rats. Synapse (2003) 47:176-183.
   PubMed Web of Science ®Google Scholar
• PILLA M, PERACHON S, SAUTEL F et al.: Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature (1999) 400:371-375.
   PubMed Web of Science ®Google Scholar
• LE FOLL B, GOLDBERG SR: Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans. Trends Pharmacol. Sci. (2005) 26:287-293.
   PubMed Web of Science ®Google Scholar